CSL

Phone: 61 3 9389 1911

Fax: 61 3 9389 1434

Type	Public
Traded as	ASX: CSL S&P/ASX 200 component
Industry	Biotechnology
Founded	1916 (Federal government department), 1994 (privatised)
Headquarters	Parkville, Melbourne, Victoria, Australia (Global),
Key people	Paul Perreault (CEO)
Products	blood plasma, vaccines, antivenom, other laboratory and medical products
Revenue	AUD$10.61 billion (2021)
Net income	USD$1.919 billion (2019)
Number of employees	30,000 person (2022)
Divisions	CSL Behring CSL Seqirus CSL Plasma CSL Vifor
Website	www.csl.com

Delivering on promises is what we do at CSL. Over a century ago in Melbourne, Victoria, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.

For detailed contact information visit location pages below.

CSL's locations around the world

OceaniaExpand

Australia

Clinical Trials sponsored by CSL

CSL Behring
CSL Plasma

Completed

Rabies Immune Plasma Booster Study

Rabies

United States
CSL Behring

Recruiting

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Complex Cardiovascular Surgery With Cardiopulmonary Bypass

United States, Japan, Canada, Mexico
CSL Behring

Recruiting

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE) (GREAT)

Hereditary Angioedemas

United Kingdom, Germany, United States, Austria, Canada
CSL Behring

Recruiting

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Hemophilia B

United States, Australia, Singapore, Hong Kong, Taiwan, South Korea, Israel, Turkey (Türkiye), Canada, Mexico, Saudi Arabia, South Africa
CSL Behring

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) (POSIBIL6ESKD)

Atherosclerotic Cardiovascular Disease in Patients With ESKD

United States, Canada, China, Australia, Taiwan, Spain, Israel, Italy, Bulgaria, Denmark, Belgium, France, Thailand, Japan, Brazil, United Kingdom, Hungary, Germany, Sweden, Argentina, Greece, Czechia, Poland, Norway, Romania, Austria, South... and more
CSL Behring

Recruiting

Two Dose Levels of Privigen in Pediatric CIDP

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States
CSL Behring

Completed

Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B

Hemophilia B

Netherlands, Germany
CSL Behring

Active, not recruiting

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

Congenital Hemophilia A

China
CSL Behring

Active, not recruiting

An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States
CSL Behring

Completed

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Acute-graft-versus-host Disease

United States, Spain, Germany, Japan, South Korea, Australia, Italy, Turkey (Türkiye)

CSL

CSL's locations around the world

Clinical Trials sponsored by CSL

List of Pharmaceutical Companies by location